New imaging combo aims to sharpen lung cancer surgery precision
NCT ID NCT07498933
First seen Mar 29, 2026 · Last updated Jun 22, 2026 · Updated 9 times
Summary
This study is testing whether a special type of PET scan (FAPI-PET/CT) and a fluorescent dye can help doctors see how well lung cancer has responded to pre-surgery treatment and find the exact tumor location during surgery. About 200 people with stage II-IIIB lung cancer will get the scan and dye before and during surgery. The goal is to see if these imaging tools can predict treatment success and help surgeons remove all cancer more accurately.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FAPI-PET/CT scan and fluorescence imaging
What this could lead to
If successful, this could improve how doctors predict whether lung cancer treatment worked and help them see tumor edges during surgery, potentially leading to more precise tumor removal.
What could go wrong
This is an early-stage diagnostic study with 200 participants, so results may not apply to all patients. The imaging techniques are still experimental and may not be accurate enough for routine use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.